[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"calcium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:calcium":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100572068","a-study-of-amorphous-calcium-carbonate-in-postmenopausal-women-100572068",false,"NCT06728462","A Study of Amorphous Calcium Carbonate in Postmenopausal Women","A Study Benchmarking FREEDOM Substudy to Evaluate the Effects of Amorphous Calcium Carbonate in Postmenopausal Women","Inclusion Criteria:\n\n1. Postmenopausal women who are 60 to 90 years of age.\n2. With BMD T-score of lower than -2.5 at the lumbar spine or total hip and -4.0 or higher at both sites. Subject who also meet the following criteria:\n\n   A arm:-Subject who meet National Health Insurance (NHI) reimbursement criteria for use of denosumab.\n\n   B arm:-Subject who does not meet NHI reimbursement criteria for use of denosumab, or who is no willing to receive denosumab treatment during study period, even meet NHI reimbursement criteria.\n3. Subject who are naïve to osteoporosis treatment or have received prior bisphosphonate treatment for less than 3 years and not within 12 months prior to screening visit.\n4. A minimum of 2 evaluable lumbar vertebrae in the L1-L4 region and 1 evaluable hip (i.e., either the left or right side).\n5. Willingness to limit additional Vitamin D3 intake to 400IU or 800IU per day during the study period.\n6. Ability to complete the entire procedure and to comply with study instructions.\n7. Will provide completed and signed written informed consent.\n\nExclusion Criteria:\n\n1. Subjects who had conditions that influence bone metabolism (i.e., Paget's disease and osteomalacia).\n2. Subject on other osteoporosis therapies, parathyroid hormone or its derivatives, corticosteroids, systemic hormone-replacement therapy, selective estrogen-receptor modulators, tibolone, calcitonin or calcitriol 6 weeks prior to screening visit.\n3. Subjects had a serum 25-hydroxyvitamin D level of less than 12 ng\u002Fml.\n4. Subjects had a BMD T-score of less than -4.0 at the lumbar spine or total hip.\n5. Subjects with any severe or more than two moderate vertebral fractures on spinal x-ray at screening visit.\n6. Subject who plan to initiate a new bisphosphonate treatment during study period.\n7. Known hypersensitivity to any component of the study drug product.\n8. Participation in any other investigational study within 30 days prior to receiving study medication.\n9. Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety.","FEMALE","60 Years","90 Years",{"count":20,"type":21},205,"ESTIMATED","INTERVENTIONAL",[24],"NA","Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.",[27,28,29,30,31],"Calcium","Osteoporosis","Bone Mineral Density","Bone Turnover Marker","Denosumab","RECRUITING","2025-03-04",{"date":35,"type":36},"2025-03-07","ACTUAL",{"date":33,"type":36},{"date":39,"type":21},"2027-03-01",{"name":41,"class":42},"Universal Integrated Corp.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100570618","thermal-ablation-versus-parathyroidectomy-for-secondary-hyperparathyroidism-100570618","NCT06709586","Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism","Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism: a Multicenter Study","Inclusion Criteria:\n\n* persistent serum iPTH (intact parathyroid hormone) levels \\> 800 pg\u002FmL；\n* resistance to calcimimetics, vitamin D, and its analogs, with ineffective conventional internal medicine comprehensive treatment；\n* severe bone pain, osteoporosis, muscle pain, ectopic soft tissue calcification, or other factors affecting quality of life；\n* imaging examinations indicating the presence of at least one enlarged parathyroid gland\n\nExclusion Criteria:\n\n* severe bleeding tendency or coagulation disorders, severe cardiopulmonary abnormalities, and abnormal vital signs such as severe hypertension, arrhythmias, and anemia","ALL","18 Years",{"count":54,"type":21},612,"OBSERVATIONAL","Secondary hyperparathyroidism (SHPT), which is frequently associated with chronic kidney disease, leads to problems such as bone pain, fractures, and cardiovascular issues, thereby affecting patients' quality of life. This clinical trial is designed to compare the efficacy of thermal ablation and surgical treatment for SHPT. Parameters including parathyroid hormone levels, serum calcium and phosphorus levels, SHPT-related symptoms (for example, bone pain, muscle weakness), and complication occurrence will be monitored. The advantages involve enabling better treatment decisions for patients, enhancing patients' quality of life, and alleviating the burden on families, in addition to augmenting the clinical knowledge of healthcare providers. However, both treatments carry risks. Thermal ablation may have problems like incomplete ablation, local tissue damage, and blood parameter changes. Surgical risks comprise bleeding, infection, adjacent tissue damage (such as the recurrent laryngeal nerve), and hypoparathyroidism. The investigators will strive to minimize these risks. This trial is of great significance for SHPT treatment, and the investigators welcome participants to contribute to the advancement of medical science in this area.",[58,59,60,27,61],"Achievement Rate","Efficacy and Safety","PTH","Clinical Symptoms","NOT_YET_RECRUITING","2024-11-26",{"date":65,"type":36},"2024-11-29",{"date":63,"type":21},{"date":68,"type":21},"2028-12-30",{"name":70,"class":71},"Chinese PLA General Hospital","OTHER"]